Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Symlin Reviewer Cautions Against Diabetes Claims For Anorexic Agents

Executive Summary

FDA should be wary of approving a diabetes claim for a drug whose mechanism of action is reducing body weight, FDA reviewer Robert Misbin, MD, said in briefing materials prepared for the advisory committee review of Amylin's Symlin.
Advertisement

Related Content

Amylin Symlin Study Will Evaluate Hypoglycemia Risk During Dose Initiation
Amylin Symlin Study Will Evaluate Hypoglycemia Risk During Dose Initiation
Roche Agenda For 2001 Includes Kytril NDA For Post-Op Use, Pegasys Launch
Advertisement
UsernamePublicRestriction

Register

PS038292

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel